A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab
Open Access
- 11 December 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
The phase 2 KNOCKOUT (NCT05283135) study evaluates higher-than-approved doses of risankizumab, an interleukin-23 inhibitor, for treatment of moderate-to-severe plaque psoriasis. Patients received either 300 or 600 mg of risankizumab at Weeks 0, 4, and 16 and were monitored for 100 weeks without further dosing. Efficacy and safety were tracked throughout the study and lesional/non-lesional tissue was evaluated by RNASeq. The primary endpoint was the change in baseline in number and/or function of tissue resident memory T cells (TRM) at week 52. The secondary endpoints were Psoriasis Areas and Severity Index (PASI) 100 at weeks 28, 40, and 52 and safety events over 100 weeks. Nine patients per treatment group completed dosing. At Weeks 28 and 52, PASI 75/90/100 responses were: 94.4%/94.4%/83.3% and 77.8%/61.1%/44.4% of all patients, respectively, with no new safety signals. At Week 52, TRM cell numbers in lesional skin were markedly reduced, with numbers similar to non-lesional TRM numbers at Week 0. High skin clearance rates with higher-than-approved initial dosing of risankizumab with prolonged maintenance of skin clearance, despite the lack of continuous dosing, represent a potential alternative treatment strategy for patients with psoriasis.Keywords
Funding Information
- AbbVie
This publication has 41 references indexed in Scilit:
- Risankizumab for Ulcerative ColitisJAMA, 2024
- The Best Psoriasis Medications EmergeJAMA Dermatology, 2024
- Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-upJournal of the American Academy of Dermatology, 2023
- Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative ReviewAdvances in Therapy, 2023
- Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic ReviewAmerican Journal of Clinical Dermatology, 2022
- Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. SecukinumabJournal of Investigative Dermatology, 2021
- Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque PsoriasisJAMA Dermatology, 2020
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsThe Lancet, 2018
- Resident T Cells in Resolved Psoriasis Steer Tissue Responses that Stratify Clinical OutcomeJournal of Investigative Dermatology, 2018
- Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trialJournal of Allergy and Clinical Immunology, 2015